Dr. Polsky on the Clinical Validity of ctDNA in BRAF-Mutant Melanoma

Dr. Polsky on the Clinical Validity of ctDNA in BRAF-Mutant Melanoma

Publication date: Mar 23, 2020

David Polsky, MD, PhD, the Alfred W. Kopf, MD, Professor of Dermatologic Oncology, Ronald O. Perelman Department of Dermatology Professor, Department of Pathology, and director of the Pigmented Lesion Service, NYU Langone Health?s Perlmutter Cancer Center, discusses the use of circulating tumor DNA (ctDNA) in the COMBI-d trial on melanoma.

Website: https://www.onclive.com

Twitter: https://twitter.com/OncLive

Facebook: https://www.facebook.com/OncLive/

LinkedIn: https://www.linkedin.com/company/onclive

Concepts Keywords
BRAF Anatomical pathology
Dermatology Cancer
LinkedIn DNA
Melanoma Melanoma
NYU Health
Oncology Clinical medicine
Pathology Medicine
PhD Circulating tumor DNA
Ronald Perelman Neoplasms
Tumor Polsky

Semantics

Type Source Name
disease MESH Melanoma
pathway KEGG Melanoma
disease MESH Pathology
disease MESH Cancer
drug DRUGBANK Coenzyme M

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *